REAL-WORLD DATA ON THE COMPARISON OF LDL-C LOWERING EFFECTS BETWEEN ALIROCUMAB AND EVOLOCUMAB

被引：0
|
作者：
Lin, D. -Y. [1 ]
Tsai, C. -L. [1 ]
Chuang, J. -Y. [2 ]
Liang, C. -H. [2 ]
Chen, Y. -H. [3 ]
Chang, Y. -H. [4 ]
Yeh, H. -I. [1 ]
Lin, C. -F. [5 ,6 ]
机构：
[1] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[2] MacKay Mem Hosp, Dept Med Educ, Taipei, Taiwan
[3] Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei, Taiwan
[4] MacKay Mem Hosp, Dept Pharm, Taipei, Taiwan
[5] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[6] MacKay Med Coll, Dept Med, New Taipei, Taiwan
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP628
引用
收藏
页码：E300 / E300
页数：1
相关论文
共 50 条
  • [31] Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications
    Wasserman, Scott M.
    Sabatine, Marc S.
    Koren, Michael J.
    Giugliano, Robert P.
    Legg, Jason C.
    Emery, Maurice G.
    Doshi, Sameer
    Liu, Thomas
    Somaratne, Ransi
    Gibbs, John P.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (05) : 423 - 432
  • [32] Low-Density Lipoprotein-Cholesterol Lowering in Real-World Patients Treated With Evolocumab
    Desai, Nihar R.
    Wade, Rolin L.
    Xiang, Pin
    Nunna, Sasikiran
    Wang, Xin
    Exter, Jason
    Habib, Mohdhar
    DiMario, Stefan
    Chen, Chi-Chang
    CIRCULATION, 2019, 140
  • [33] ALIROCUMAB TITRATION STRATEGY ALLOWS INDIVIDUALIZED LDL-C REDUCTION IN A REAL WORLD SETTING: RESULTS FROM ODYSSEY OLE (LONG TERM COHORT)
    Dufour, Robert
    Hovingh, G. Kees
    Guyton, John
    Langslet, Gisle
    Baccara-Dinet, Marie
    Din-Bell, Chantal
    Manvelian, Garen
    Farnier, Michel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1710 - 1710
  • [34] Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering A Systematic Review and Meta-analysis
    Navarese, Eliano P.
    Robinson, Jennifer G.
    Kowalewski, Mariusz
    Kolodziejczak, Michalina
    Andreotti, Felicita
    Bliden, Kevin
    Tantry, Udaya
    Kubica, Jacek
    Raggi, Paolo
    Gurbel, Paul A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (15): : 1566 - 1579
  • [35] Evolocumab real-world data: five-year experience of an Italian hospital
    Bellato, N.
    Campanardi, M. C.
    Calzavara, E.
    Nobili, S.
    De Vivo, G.
    Cambareri, M.
    Veneziano, C.
    Atzeni, F.
    Andena, M.
    Ciceri, E.
    Richelmi, P.
    Vimercati, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (03) : 791 - 791
  • [36] Efficacy and Barriers to Evolocumab Therapy in Real-World, High Risk Secondary Prevention Patients Not at LDL Targets
    Pandey, Avinash K.
    Bajaj, Harpreet
    Garg, Vinay
    Pandey, A. Shekhar
    Verma, Subodh
    CIRCULATION, 2017, 136
  • [37] LDL-C LOWERING EFFICACY OF EVOLOCUMAB (AMG 145) COULD REDUCE APHERESIS IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS IN GERMANY
    Villa, G.
    Schmid, T.
    Lothgren, M.
    Michailov, G.
    VALUE IN HEALTH, 2014, 17 (07) : A504 - A504
  • [38] Studies into the association between LDL-C lowering and cognitive function: time to forget about it?
    Ibrahim, Shirin
    Reeskamp, F. Laurens
    Hovingh, G. Kees
    SCIENCE BULLETIN, 2021, 66 (16) : 1614 - 1615
  • [39] HEAD TO HEAD EFFICACY COMPARISON OF ALIROCUMAB 75 AND 150 MG VS EVOLOCUMAB 140 MG IN REAL WORLD PATIENTS
    Min, S.
    Mahida, C.
    Schlam, I.
    Huda, A.
    Wang, P.
    Goldenberg, N.
    Glueck, C. J.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (04) : 815 - 815
  • [40] Glaucoma: Real-World Data on Lowering Intraocular Pressure with SLT
    Bitzer, Michaela
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2020, 237 (10) : 1166 - 1166
12345